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The human microbiota comprises trillions of microbes, and the relationship between
cancer and microbiota is very complex. The impact of fecal microbiota alterations on
colorectal cancer (CRC) pathogenesis is emerging. This study analyzed changes in the
microbial composition in CRC subjects with both fecal microbiota and gut microbe-
derived extracellular vesicles (EVs). From August 2017 to August 2018, 70 CRC patients
and 158 control subjects were enrolled in the study. Metagenomic profiling of fecal
microbiota and gut microbe-derived EVs in stool was performed using 16S ribosomal
DNA sequencing. Relative abundance, evenness, and diversity in both the gut microbiota
and gut microbe-derived EVs were analyzed. Additionally, microbial composition changes
according to the stage and location of CRC were analyzed. Microbial composition was
significantly changed in CRC subjects compared to control subjects, with evenness and
diversity significantly lower in the fecal microbiota of CRC subjects. Gut microbe-derived
EVs of stool demonstrated significant differences in the microbial composition, evenness,
and diversity in CRC subjects compared to the control subjects. Additionally, microbial
composition, evenness, and diversity significantly changed in late CRC subjects
compared to early CRC subjects with both fecal microbiota and gut microbe-derived
EVs. Alistipes-derived EVs could be novel biomarkers for diagnosing CRC and predicting
CRC stages. Ruminococcus 2-derived EVs significantly decreased in distal CRC subjects
than in proximal CRC subjects. Gut microbe-derived EVs in CRC had a distinct microbial
composition compared to the controls. Profiling of microbe-derived EVs may offer a novel
biomarker for detecting and predicting CRC prognosis.
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Colorectal cancer (CRC) has become a global health problem
because of the increasing incidence of CRC in young adults (1, 2).
Western dietary patterns and obesity have been strongly linked
to CRC development (3, 4). Various studies have suggested that
the pathogenesis of CRC is influenced not only by genetic factors
but also by gut microbial composition altered due to ingested
food or environmental factors. Gut microbiota induce oxidative
stress and DNA damage in response to chronic inflammation,
cell proliferation, and the production of metabolites such as
butyrate (5). In animal studies, Fusobacterium nucleatum is
associated with CRC pathogenesis by expressing a bacterial cell
surface adhesion component, which can bind to host E-cadherin
(6, 7). Enterotoxigenic Bacteroides fragilis is enriched in human
CRC, resulting in cell morphology changes, E-cadherin cleavage
stimulation, and colonic barrier function reduction (8).
Efforts to develop microbe-based cancer therapy have attracted
more than 100 years from Coley’s toxin in patients with bone
cancer (9). Immunotherapy, including anti-programmed death
receptor-1 (PD-1) inhibitors and anti-cytotoxic T-lymphocyte
associated protein 4 (CTLA-4), provides a therapeutic response
by modulating the gut microbiota (10, 11). Several approaches,
including probiotics such as VSL#3 and LGG, could alter the gut
microbiota composition (12, 13). Probiotics may regulate the
immune system and inhibit the progression of CRC. Dietary
changes by eliminating animal fat and a high-fiber diet may
ultimately be a considered cancer therapy in some studies
(14, 15). Nevertheless, the human microbiota comprises trillions
of microbes, and the relationship between cancer and microbiota
is very complex. Due to the heterogeneity of the microbiota, there
are many limitations to finding therapeutic agents targeting
specific microbiota.
Gut microbes, including gram-negative bacteria and some
gram-positive bacteria, can produce extracellular vesicles (EVs),
also called nanovesicles, and are upregulated during cell
activation and growth during cancer development (16). Excess
EVs can be released into the circulation, including plasma, saliva,
gastric juice, and intestinal luminal liquid. There are many
approaches for studying EV-associated RNA, membrane lipids,
and proteomic composition of EVs (17, 18). EV-based early
diagnostic biomarkers in patients with gastrointestinal cancer are
challenging areas (19). Kanwar et al. developed a microfluidic
device for circulating exosome characterization in patients with
pancreatic cancer patients (20). Choi et al. found some proteins
in colorectal cancer-derived EVs by proteomic analysis (21, 22).
However, to the best of our knowledge, there have been very few
reports on the development of CRC biomarkers by 16S
ribosomal DNA sequencing metagenomic profiling with EV
samples isolated from stool samples (23).
This study hypothesized that microbe-derived EVs interact
with the gut microbiota and are associated with CRCAbbreviations: CRC, colorectal cancer; EV, extracellular vesicle; PD-1,
programmed death receptor-1; CTLA-4, cytotoxic T-lymphocyte associated
protein 4; out, operational taxonomic unit; PCoA, principal coordinate analysis;
ROC, receiver operating characteristic; RF, random forest; AUC, area under the
curve; IBD, inflammatory bowel disease.
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were analyzed and compared with control subjects of microbiota
with both stool samples and microbe-derived EV samples.
Additionally, differences in microbial composition were
analyzed according to the stage and location of CRC.MATERIALS AND METHODS
Patients and Sampling
Between August 2017 and August 2018, 158 stool samples were
collected from control subjects, and 70 stool samples were
collected from colorectal cancer patients who visited the CRC
clinic at Seoul National University Bundang Hospital
(Seongnam, Republic of Korea) and Chung-Ang University
College of Medicine (Seoul, Republic of Korea) before
undergoing any treatment. The exclusion criteria were as
follows: (i) patients who had been diagnosed with gastric
cancer, colorectal cancer, or other malignant diseases in the
past and had undergone surgery and chemotherapy; (ii) patients
who had been diagnosed with gastric dysplasia or gastric
adenoma; (iii) pregnant women; (iv) patients who had been
taking antibiotics or probiotics within last three months; and
(v) patients who declined to participate in the study. For the
enrolled patients, extensive medical data were collected every
time they visited our clinic using electronic medical records.
Fecal samples were self-sampled and stored at -20°C, transported
to the laboratory, and frozen at -70°C. Control stool samples
were selected from a previously collected cohort of healthy
patients above 40 years of age who had abdominal symptoms
but were not diagnosed with irritable bowel syndrome. There was
no overlap of participants in the control group between previous
studies. This study was approved by the Institutional Review
Board of Seoul National University Bundang Hospital (IRB No:
B-1708/412–301). Written informed consent for the use of
medical records was obtained from all the participants. 23
CRC patients (only fecal microbiota samples) overlap with
those in previous reports (24). 31 CRC patients (both fecal
microbiota and gut microbe-derived EV samples) overlap with
those in previous reports (23).
Extracellular Vesicles (EV) Isolation and
DNA Extraction
Human stool samples were filtered through a cell strainer after
being diluted in 10 mL of PBS for 24 h. The samples were
centrifuged at 10,000 × g for 10 min at 4°C to separate EVs from
stool samples. After centrifugation, stool sample pellets
contained bacterial cells, and the supernatant of stool samples
contained EVs. Bacteria and foreign particles were thoroughly
eliminated from the stool sample supernatant by sterilizing the
supernatant through a 0.22-µm filter. To extract DNA from
bacterial cells and bacterial EVs, bacteria and EVs were boiled for
40 min at 100°C. To eliminate the remaining floating particles
and waste, the supernatant was collected after 30 min of
centrifugation at 13,000 rpm at 4°C. DNA was extracted using
a DNeasy PowerSoil Kit (QIAGEN, Germany) according to the
instructions of the manufacturer. DNA extracted from bacterialSeptember 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCcells and EVs in each sample was quantified using a QIAxpert
system (QIAGEN, Germany).
Bacterial Metagenomic Analysis Using
Extracellular Vesicles (EV) DNA
Bacterial genomic DNA was amplified with 16S_V3_F (5′-TCGT
CGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGG
NGGCWGCAG-3′) and 16S_V4_R (5′-GTCTCGTGGGCTCG
GAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC-3′) primers, specific for the V3-V4 hypervariable regions
of the 16S rRNA gene. Libraries were prepared using PCR
products according to the MiSeq System guide (Illumina, USA)
and quantified using the QIAxpert (QIAGEN, Germany). Each
amplicon was quantified, set equimolar ratio, pooled, and
sequenced on a MiSeq platform (Illumina, USA) according to
the recommendations of the manufacturer.
Analysis of Bacterial Composition
in the Microbiota
Paired-end reads that matched the adapter sequences were
trimmed using Cutadapt version 1.1.6, with a minimum
overlap of 11, a maximum error rate of 15%, and a minimum
length of 10 (25). The resulting FASTQ files containing paired-
end reads were merged with CASPER version 0.8.2, with a
mismatch ratio of 0.27, and then quality-filtered using the
Phred (Q) score-based criteria described by Bokulich (26, 27).
Any reads shorter than 350 bp or longer than 550 bp after
merging were discarded. A reference-based chimera detection
step was conducted with VSEARCH version 2.3.0 against the
SILVA gold database (28, 29) to identify the chimeric sequences.
Sequence reads were clustered into operational taxonomic units
(OTUs) using VSEARCH with an open clustering algorithm
under a 97% sequence similarity threshold. The representative
sequences of the OTUs were finally classified using the SILVA
132 database with UCLUST (parallel_assign_taxonomy_
uclust.py script in QIIME version 1.9.1) under default
parameters (30). The original contributions presented in the
study are publicly available in NCBI. Raw reads of the fecal
microbiota and microbe-derived EVs for colorectal cancer
patients were deposited into the NCBI SRA database,
respectively (Accession Numbers: SRR15182562–SRR15182631;
SRR15182632–SRR15182701). Raw reads of the fecal microbiota
and microbe-derived EVs for control patients from three datasets
were deposited into the NCBI SRA database respectively (dataset
1: SRR15056567–SRR15056766; SRR15056787–SRR15056992;
dataset 2: SRR15244175-SRR15244358; SRR15245161-
SRR15245345; dataset 3: SRR15204197-SRR15221118;
SRR15243500-SRR15243683) (Supplementary Data).
Statistical Analyses
Group comparisons for diversity metrics were conducted and
graphed using R (version 3.6.3). a-Diversity (observed OTUs,
Shannon index, and phylogenetic diversity) was compared by the
decimal log-transformed relative abundance fecal microbiota
between groups using the Wilcoxon rank-sum test (R package
‘microbiome version 1.9.19’). Group distances for b-diversityFrontiers in Oncology | www.frontiersin.org 3(weighted UniFrac metric and unweighted UniFrac metric) were
generated with permutational analysis of variance (PERMANOVA)
using 1000Monte Carlo permutations (R package ‘phyloseq version
1.30.0’ and ‘vegan version 2.5.6’) and visualized with principal
coordinate analysis (PCoA) plots. Receiver operating characteristic
(ROC) curves of the random forest (RF) model were obtained using
age, sex, and taxa for predicting CRC. The RFmethod was used with
the RandomForestClassifier function of the sklearn package in
Python (version 2.7.17), and a 10-fold cross-validation was
applied to the training set. For ROC curves and the area under
the curve (AUC), the pROC package in R was utilized. Discriminate
taxa (>0.1% abundance) between the groups were identified using
Welch’s t-test. Adjusted p-values controlling the false discovery rate
(FDR) were reported where appropriate.RESULTS
Fecal Microbiota Composition in
Colorectal Cancer (CRC) Patients and
Control Subjects
16S rRNA filtered gene sequences (Supplementary Table 1)
were obtained from 228 stool samples (70 CRC subjects and 158
control subjects). The overall composition of the gut microbiota
was altered in CRC subjects compared to that in the controls. Gut
microbiota composition profiles were compared at the phylum,
family, and genus levels (Figures 1A–C). CRC subjects showed a
significant enrichment of Bacteroidetes phylum and depletion of
Actinobacteria phylum (p < 0.001, Table 1). Within the phylum
Bacteroidetes, relative enrichment was prominent for the family
Bacteroidaceae, including genus Bacteroides (Table 1). Within
Actinobacteria, relative depletion was prominent for the
Bifidobacterium (Bifidobacterium genus) family in CRC
subjects. Although there was no overall difference at the
phylum level, several compositional changes were found at the
family and genus levels. The relative abundance of the family
Clostridiaceae 1 (genus Clostridium sensu stricto 1), Family XIII
(genus Family XIII AD3011 group), and Erysipelotrichaceae
(genus Erysipelotrichaceae UCG-003) was lower in the CRC
group than in the control group (Table 1). Ruminococcus I,
Ruminococcaceae UCG-013 (family Ruminococcaceae), Blautia
[Eubacterium] hallii group, and Lachnospiraceae NC2004 group
(family Lachnospiraceae) were also significantly depleted in the
CRC group (Table 1).
Gut microbial community structure, assessed by richness and
diversity, demonstrated a significantly lower richness and
diversity in CRC subjects than in control subjects (Figures 1D
and 2A, B). A combined ROC analysis using clinical data and
fecal microbiota revealed an AUC of 0.923 (Figure 3).
Gut Microbe-Derived Extracellular
Vesicles Composition in Colorectal Cancer
(CRC) Patients and Control Subjects
We compared microbiota with gut microbe-derived EVs between
CRC subjects and control subjects at the phylum, family, and genus
levels (Figures4A–C). CRCsubjects showeda significant enrichmentSeptember 2021 | Volume 11 | Article 650026
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phylum (p = 0.002, Table 2). Within the Firmicutes phylum, the
relative abundances of Clostridiaceae 1 (genus Clostridium sensu
stricto 1), Erysipelotrichaceae (genus Turicibacter) ,
Peptostreptococcaceae (genus Romboutsia and Terrisporobacter),
Veillonellaceae (genus Dialister), Staphylococcaceae (genus
S taphy l o co c cu s ) , and Ac idaminoco c ca c eae ( g enus
Phascolarctobacterium) was lower in the control group (Table 2).
Relative enrichmentwasprominent for the familyErysipelotrichaceaeFrontiers in Oncology | www.frontiersin.org 4(genus Catenibacterium, Erysipelotrichaceae UCG-003),
Ruminococcaceae (genus Faecalibacterium, Ruminococcus 2),
Lachnospiraceae [genus Blautia, (Eubacterium) hallii group,
(Ruminococcus) torque group, Oribacterium, Dorea] (Table 2).
Within the Verrucomicrobia phylum, the Akkermansiaceae (genus
Akkermansia) family was significantly lower in the CRC group than
in the control group (Table 2). Within the Actinobacteria phylum, a
significant enrichment of the family Coriobacteriaceae (genus




FIGURE 1 | Relative abundance plots of the gut microbiota of control (n = 158) subjects and CRC subjects (n = 70) (A) at the phylum, (B) family, and (C) genus levels.
(D) Boxplots of alpha diversity indices comparing CRC with control in the gut microbiota. ***p < 0.005 and *p < 0.05. CRC; colorectal cancer, OTU; operational
taxonomic unit.September 2021 | Volume 11 | Article 650026
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and gut microbial community structure, assessed by richness
and diversity, demonstrated a significant difference in richness
and diversity between the CRC and control subjects (Figures 2C,
D, 4D). A combined ROC analysis using clinical data and gut
microbe-derived EVs revealed an AUC of 0.963 (Figure 3).Differences in the Microbial Composition
According to the Colorectal Cancer (CRC)
Stage
We analyzed the differences in the microbial composition
according to the CRC stage. Out of the 70 patients with CRC,Frontiers in Oncology | www.frontiersin.org 562 patients were in stages I, II, or III, defined as early CRC, and 8
patients were in stage IV, defined as late CRC. In fecal
microbiota, late CRC subjects tended to have an enrichment of
Bacteroidetes and depletion of Actinobacteria compared with
early CRC subjects (Figures 5A–C). In fecal microbiota, within
Bacteroidetes, relative enrichment was prominent for the family
Marinifilaceae (genus Odoribacter) and Rikenellaceae (genus
Alistipes) in late CRC subjects than in early CRC subjects
before adjustment (Supplementary Table 2). Odoribacter and
Alistipes genera were significantly increased in CRC subjects
compared to control subjects (Table 1). Microbial composition
changes in control and CRC subjects and those of early and late
CRC subjects were similar. Relative depletion was prominent forTABLE 1 | Taxa showing a significant different in the abundance between CRC with control in the gut microbiota.
Taxon t-statistic Unadjusted p-value Adjusted p-value Reference
Phylum Firmicutes 　 　 　
Family Clostridiaceae 1 -4.17 <0.001 0.002 (31)
Genus Clostridium sensu stricto 1 -4.17 <0.001 0.004
Family Family XIII -3.73 <0.001 0.004 (32)
Genus Family XIII AD 3011 group -3.73 <0.001 0.008
Family Erysipelotrichaceae -3.50 <0.001 0.016 (31)
Genus Erysipelotrichaceae UCG-003 -3.50 0.001 0.042
Genus Turicibacter -2.89 0.004 0.129 (31)
Family Ruminococcaceae (31, 33)
Genus Ruminococcus 1 -5.81 <0.001 0.004 (34, 35)
Genus Ruminococcaceae UCG-013 -3.78 <0.001 0.004
Genus Butyricicoccus -2.68 0.009 0.224 (36)
Genus Subdoligranulum -2.59 0.012 0.286
Family Lachnospiraceae (31, 34)
Genus Blautia -4.27 <0.001 0.009 (35)
Genus [Eubacterium] hallii group -3.82 <0.001 0.003 (37)
Genus Lachnospiraceae NC2004 group -3.45 <0.001 0.003
Genus [Eubacterium] ventriosum -3.08 0.004 0.117 (37)
Genus [Ruminococcus] torques group -2.15 0.037 0.553
Family Peptostreptococcaceae -2.80 0.008 0.128 (31, 33)
Genus Romboutsia -3.15 0.002 0.071
Genus Terrisporobacter -2.43 0.020 0.393
Family Christensenellaceae -2.76 0.007 0.124 (31)
Genus Christensenellaceae R-7 group -2.76 0.007 0.207
Family Leuconostocaceae -2.77 0.008 0.124 (38)
Genus Weissella -2.77 0.008 0.209
Family Lactobacillaceae -2.37 0.022 0.234 (31)
Genus Lactobacillus -2.37 0.022 0.405
Phylum Bacteriodetes 6.55 <0.001 <0.001
Family Bacteroidaceae 5.26 <0.001 0.002
Genus Bacteroides 5.26 <0.001 0.004 (34, 39)
Family Marinifilaceae 2.69 0.009 0.128
Genus Odoribacter 2.69 0.009 0.227 (31, 33, 34, 39)
Family Rikenellaceae 2.47 0.015 0.185 (31)
Genus Alistipes 2.47 0.015 0.325 (33, 34)
Family Tannerellaceae 2.03 0.046 0.390
Genus Parabacteroides 2.03 0.046 0.613 (34)
Phylum Actinobacteria -5.82 <0.001 <0.001
Family Bifidobacteriaceae -5.93 <0.001 0.002 (31)
Genus Bifidobacterium -5.93 <0.001 0.004 (34, 35)
Family Eggerthellaceae -2.52 0.014 0.185
Genus Eggerthella -2.52 0.014 0.321 (33)
Family Actinomycetaceae -2.36 0.021 0.234
Genus Actinomyces -2.36 0.021 0.405 (31)September 2021 | Volume 11The change of column (log2 fold) represents the multiplicative change in taxa abundance from CRC to control.
Negative numbers represent a trend of decreasing abundance in CRC group compared with control group.
The data (p < 0.05) was provied as bold values.| Article 650026
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Frontiers in Oncology | www.frontiersin.org 6the family Prevotellaceae (genus Prevotella 9) in late CRC
subjects. Within Firmicutes, relative depletion was prominent
for the family Ruminococcaceae (genus Butyricicoccus) in late
CRC subjects (Supplementary Table 2). Butyricicoccus was
significantly decreased in CRC subjects compared to control
subjects (Table 1).
In the microbiota with gut microbe-derived EVs, relative
enrichment was prominent for the family Rikenellaceae
(genus Alistipes) in late CRC subjects compared to early CRC
subjects before adjustment (Figures 6A–C and Supplementary
Table 3). Within Firmicutes, relative enrichment was
prominent for the family Acidaminococcaceae (genus
Phascolarctobacterium), and relative depletion was prominent
for the family Lactobacillaceae (genus Lactobacillus) in late CRC
subjects compared to early CRC subjects before adjustment
(Supplementary Table 3).
CRC fecal microbiota and CRC gut microbe-derived EV
composition and gut microbial community structure, assessed
by richness and diversity, demonstrated a significantly different
richness and diversity in late CRC subjects than in early CRC
subjects. (Figures 2A, B, 5D and 6D).A
C D
B
FIGURE 2 | Principal coordinate analysis (PCoA) plots of beta diversity analysis of control, early CRC, and late CRC patients in the gut microbiota (A–B) and the gut
microbe-derived extracellular vesicles (C–D). Between-sample dissimilarities were measured by unweighted UniFrac distances (A, C) and weighted UniFrac distances
(B, D). Permutational multivariate analysis of variance (PERMANOVA) was performed to analyze statistical significance (p = 0.001).FIGURE 3 | A combined receiver operating characteristic (ROC) analysis
using clinical data and gut microbe-derived EVs.September 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCDifferences in the Microbial Composition
According to the Colorectal Cancer
(CRC) Location
We also analyzed the differences in the microbial composition
according to the CRC location. Of the 70 patients with CRC, 20 had
proximal CRC and 50 had distal CRC. There were no significant
differences in gut microbial composition changes between theFrontiers in Oncology | www.frontiersin.org 7proximal and distal CRC subjects (Figures 7A–C). In microbiota
with gut microbe-derived EVs, within the Firmicutes phylum,
relative depletion was prominent for family Ruminococcaceae
(genus Ruminococcus 2) in the distal CRC subjects compared to
proximal CRC subjects (Figures 8A–C and Supplementary
Table 4). Alpha diversity was not different between distal




FIGURE 4 | Relative abundance plots of gut microbe-derived extracellular vesicles of control (n = 158) subjects and CRC subjects (n = 70) (A) at the phylum,
(B) family, and (C) genus levels. (D) Boxplots of alpha diversity indices comparing CRC with control in gut microbe-derived extracellular vesicles. ***p < 0.005. CRC;
colorectal cancer, OTU; operational taxonomic unit.September 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCmicrobe-derived EVs (Figures 7D and 8D). Microbial community
structure was assessed by evenness with both stool and microbe-
derived EVs, but distal CRC subjects did not differ from proximal
CRC subjects.DISCUSSION
The human gut microbiota comprises trillions of microbes, and
20% of human malignancies are caused by dysbiosis (40). In the
past decade, metagenomic sequencing has broadened our
understanding of microbial composition. The gut microbiota
plays an important role in CRC initiation by chronic
inflammation, which affects the intestinal epithelial cells. FecalFrontiers in Oncology | www.frontiersin.org 8and mucosal microbial changes in CRC patients have been
studied; however, no consistent patterns among these studies
have been observed (6, 41–43).
This study analyzed stool profiling to identify the changes in
microbial composition in CRC patients in South Korea. CRC
subjects showed a significant enrichment of Bacteroidetes
phylum and depletion of Actinobacteria phylum. At the genus
level, the relative abundances of Bacteroides, Odoribacter,
Alistipes, and Parabacteroides were higher in the CRC patients
than in the healthy controls. The top five genera dominant in
CRC patients were Bifidobacterium, Ruminococcus 1, Blautia,
Clostridium sensu stricto 1, and the Eubacterium hallii group. In
previous studies, patients with CRC had higher proportions of
pathogenic bacteria, including Bacteroides, Odoribacter, and
Alistipes, and fewer Bifidobacterium, Ruminococcus, and
Blautia, similar to our results (34, 44). Putrefactive bacteria
such as Alistipes and Bacteroides can produce short-chain fatty
acids and promote chronic intestinal inflammation (45). The
decrease in Bifidobacterium, Ruminococcus, and Blautia, which
act as potential probiotics and function as antibacterial agents,
could enhance CRC development (35). Additionally, we found
that the richness and diversity of the fecal microbiota of patients
with CRC were significantly lower than those of the healthy
controls. Dongmei et al. also suggested that alpha diversity was
significantly higher in the control subjects than in the CRC
subjects (46). The difference in fecal microbial composition
between the CRC and control subjects suggests that fecal
microbiota could be a possible diagnostic biomarker in
the future.
To discover a new effective biomarker of CRC stages, we also
analyzed the different genera between early and late CRC
subjects. We found that the Odoribacter and Alistipes genera
were significantly increased not only in late CRC subjects
compared to early CRC subjects but also in CRC subjects
compared to control subjects. Odoribacter and Alistipes genera
could be novel biomarkers for diagnosing CRC and predicting
CRC stages. Genus Alistipes is an emerging gut bacteria related to
inflammation, cancer, and mental health, as per a recent review
(45). Alistipes evokes colitis and proximal colon cancers in
IL10-/- mice (47). In addition, Butyricicoccus was significantly
decreased in CRC subjects compared to control subjects.
Butyricicoccus is a gut butyrate-producing bacterium that
improves the clinical outcome of CRC by administration of
Butyricicoccus pullicaecorum, as demonstrated in a previous
mouse model (48). This result suggests that Butyricicoccus
might be a novel pharmacological agent to prevent
CRC pathogenesis.
To the best of our knowledge, there are few studies on the
composition of gut microbe-derived EVs in CRC patients
compared with controls (23). In principal coordinate analysis,
the microbial community structure of the CRC gut microbe-
derived EVs was different from that of the control subjects. This
study showed that the composition of gut microbe-derived EVs
differed significantly from that of fecal microbiota. These results
indicate that gut microbe-derived EVs might be a better novel
biomarker than fecal microbiota. Gut microbe-derived EVsTABLE 2 | Taxa showing a significant different in the abundance between CRC





Phylum Firmicutes 3.16 0.002 0.008
Family Clostridiaceae 1 -3.36 0.001 0.019
Genus Clostridium sensu stricto 1 -3.36 0.001 0.003
Family Erysipelotrichaceae 3.28 0.001 0.019




Genus Turicibacter -2.00 0.043 0.541
Family Ruminococcaceae 4.22 <0.001 0.002
Genus Faecalibacterium 3.41 <0.001 0.020
Genus Ruminococcus 1 2.96 0.004 0.089
Genus Ruminococcus 2 2.23 0.028 0.028
Family Lachnospiraceae
Genus Blautia 3.78 <0.001 0.012




Genus Oribacterium 3.79 <0.001 0.012
Genus Dorea 3.91 0.004 0.018
Genus Lachnospiraceae UCG-008 2.52 0.012 0.230
Family Peptostreptococcaceae -3.25 0.003 0.033
Genus Romboutsia -4.35 <0.001 0.001
Genus Terrisporobacter -3.56 <0.001 0.003
Genus Intestinibacter -3.07 0.004 0.092
Family Veillonellaceae -6.10 <0.001 0.002
Genus Dialister -6.10 <0.001 0.004
Family Staphylococcaceae -4.61 <0.001 0.002
Genus Staphylococcus -4.61 <0.001 0.004
Family Acidaminococcaceae -3.28 0.001 0.018
Phylum Proteobacteria
Family Moraxellaceae
Genus Enhydrobacter -2.15 0.034 0.476
Phylum Actinobacteria
Family Coriobacteriaceae 4.78 <0.001 0.004
Genus Collinsella 4.78 <0.001 0.007
Phylum Verrucomicrobia -3.77 <0.001 0.002
Family Akkermansiaceae -3.77 <0.001 0.004
Genus Akkermansia -3.77 <0.001 0.012The change of column (log2 fold) represents the multiplicative change in taxa abundance
from CRC to control.
Negative numbers represent a trend of decreasing abundance in CRC group compared
with control group.
The data (p < 0.05) was provied as bold values.September 2021 | Volume 11 | Article 650026
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acids from cells to other cells as nanocarriers (49). Tumors and
other cells secrete EVs, and tumor-derived EVs can stimulate
tumor progression, invasion, angiogenesis, and metastasis (50).
Gut microbe-derived EVs in CRC patients may play a pivotal role
in tumorigenesis. Several studies have examined EVs in CRC
patients and animal models of IBD (51, 52). In the present
study, Clostridium sensu stricto 1, Turicibacter, Romboutsia,Frontiers in Oncology | www.frontiersin.org 9Terrisporobacter, Dialister, Staphylococcus, Phascolarctobacterium,
and Akkermansia-derived EVs could be effective therapeutic
candidates for CRC treatment. Additionally, Catenibacterium,
Erysipelotrichaceae UCG-003, Faecalibacterium, Ruminococcus 2,
Blautia [Eubacterium] hallii group, Ruminococcus torques group,
Oribacterium, Dorea, and Collinsella-derived EVs could be novel
biomarkers for CRC diagnosis. Although it is difficult to determine




FIGURE 5 | Relative abundance plots of the gut microbiota of early CRC (n = 62) and late CRC (n=8) (A) at the phylum, (B) family, and (C) genus levels. (D) Boxplots
of alpha diversity indices comparing late CRC with early CRC in the gut microbiota. *p < 0.05. CRC; colorectal cancer, OTU; operational taxonomic unit.September 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCEVs between CRC patients and healthy controls, the development
of targeted analysis of cancer-derived EVs with specimens for the
diagnosis and treatment monitoring in clinical settings has
gained attention and challenges in recent years (53). We
performed ROC analysis and established a prediction model for
CRC diagnosis using gut-derived EVs compared to fecal
microbiota. The microbiota enhanced the performance forFrontiers in Oncology | www.frontiersin.org 10predicting CRC diagnosis compared to the model with only
clinical data. Among the microbiota data, gut-derived EVs
outperformed fecal microbiota.
According to the CRC stage, Alistipes-derived EVs were
significantly increased not only in late CRC subjects compared
to early CRC subjects but also in CRC subjects compared




FIGURE 6 | Relative abundance plots of gut microbe-derived extracellular vesicles of early CRC (n = 62) and late CRC (n=8) (A) at the phylum, (B) family, and
(C) genus levels. (D) Boxplots of alpha diversity indices comparing late CRC with early CRC in gut microbe-derived extracellular vesicles. **p < 0.01 and *p < 0.05.
CRC; colorectal cancer, OTU; operational taxonomic unit.September 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCbiomarkers for diagnosing CRC and predicting CRC
stages. Phascolarctobacterium-derived EVs were significantly
increased, and Lactobacillacea-derived EVs were significantly
decreased in late CRC subjects compared to early CRC
subjects. Gut microbe-derived EVs in CRC patients could play
an important role in the development and growth of CRC.
Studies have identified metagenomic biomarkers for CRC
formation (54). We analyzed the differences in the microbialFrontiers in Oncology | www.frontiersin.org 11composition according to the CRC location. In the microbiota
with gut microbe-derived EVs, Ruminococcus 2 was lower in the
distal CRC subjects than in the proximal CRC subjects. The
microenvironment could affect the pathogenesis of CRC
development, and enrichment of Ruminococcus 2 could be
associated specifically with proximal CRC development.
However, the difference according to the CRC stage was more




FIGURE 7 | Relative abundance plots of the gut microbiota of proximal CRC (n = 20) versus distal CRC (n = 50) (A) at the phylum, (B) family, and (C) genus levels.
(D) Boxplots of alpha diversity indices comparing distal CRC with proximal CRC in the gut microbiota. CRC; colorectal cancer, OTU; operational taxonomic unit.September 2021 | Volume 11 | Article 650026
Park et al. Gut Microbe-Derived Vesicles in CRCOur study has several limitations. First, although our research
team has approved the EV isolation method in previous studies,
ultracentrifugation with a relatively low number of turns could
influence our results. Second, future studies for dynamic light
scattering (DLS) or transmission electron microscopy (TEM)
images to trace the size of vesicles are warranted. Third, we
discovered candidate microbe-derived EVs for CRC prediction,Frontiers in Oncology | www.frontiersin.org 12but we did not validate them. Further study for validation with
PCR on the target taxa will be warranted to quantify the
microbe-derived EVs for CRC prediction.
In summary, this is a report on the metagenomic analysis
of gut microbe-derived EVs in CRC patients. Profiling of
microbe-derived EVs may offer a novel biomarker for detecting




FIGURE 8 | Relative abundance plots of gut microbe-derived extracellular vesicles of proximal CRC (n = 20) versus distal CRC (n = 50) (A) at the phylum, (B) family,
and (C) genus levels. (D) Boxplots of alpha diversity indices comparing distal CRC with proximal CRC in gut microbe-derived extracellular vesicles. CRC; colorectal
cancer, OTU; operational taxonomic unit.September 2021 | Volume 11 | Article 650026
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